Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Taiwan / NCT04948437
Active, not recruiting Observational

Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer

NCT04948437 · tracked via the Priya Life Science Taiwan tracker
Sponsor
National Taiwan University Hospital
Phase
Observational
Started
2021-08-19
Last updated
2026-04-13

Condition(s) studied

Thyroid CancerPapillary Thyroid CancerFollicular Thyroid Cancer

Study summary

Now, the investigators carried out a prospective study enrolling patients with thyroid cancer, who had received ablative thyroidectomy and /or radioactive iodine therapy for two more years. The investigators' study already enrolled seventy-three patients with thyroid cancer, and the investigators plan to enroll 30 new patients in this consecutive research study. All patients received total thyroidectomy under clinically surgical judgement in initial therapeutic option. The investigators also further found some difference between papillary thyroid cancer and follicular thyroid cancer, and the investigators will continue annually to closely monitor the change of U-Ex Tg and urinary exosomal galectin-3 between differently cellular types of thyroid cancers.

Eligibility

Sex
ALL
Min age
20 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * diagnosed patients with thyroid papillary, follicular and anaplastic thyroid cancer, post-operation follow up Exclusion Criteria: * unclearly diagnosed patients with thyroid papillary, follicular and anaplastic thyroid cancer

Primary outcome measure(s)

  • Change of serum thyroglobulin level — Within 36 months
    Thyroid function test
  • Change of serum free T4 level — Within 36 months
    Thyroid function test
  • Change of serum TSH level — Within 36 months
    Thyroid function test
  • Change of anti-thyroglobulin level — Within 36 months
    Thyroid function test
  • Urinary exosomal thyroglobulin detection — Within 36 months
    Urinary exosomal biomarker
  • Urinary exosomal galectin-3 detection — Within 36 months
    Urinary exosomal biomarker
  • Urinary exosomal calprotectin A9 detection — Within 36 months
    Urinary exosomal biomarker
  • Urinary exosomal transketolase detection — Within 36 months
    Urinary exosomal biomarker
  • Urinary exosomal keratin 19 detection — Within 36 months
    Urinary exosomal biomarker
  • Urinary exosomal angiopoietin-1 detection — Within 36 months
    Urinary exosomal biomarker
  • Urinary exosomal tissue inhibitor of metalloproteinase detection — Within 36 months
    Urinary exosomal biomarker
  • Urinary exosomal keratin 8 detection — Within 36 months
    Urinary exosomal biomarker
  • Urinary exosomal calprotectin A8 detection — Within 36 months
    Urinary exosomal biomarker
  • Urinary exosomal annexin II detection — Within 36 months
    Urinary exosomal biomarker
  • Urinary exosomal afamin detection — Within 36 months
    Urinary exosomal biomarker

Trial sites (1)

FacilityCityRegionStatus
Chih-Yuan Wang, M.D Taipei Taiwan

More National Taiwan University Hospital trials in Taiwan

Correlation Between Soft Tissue Displacement and Functional Performance in Orthopedic Patients Starting soon
Home-based Cardiac Rehabilitation With Spot-jogging Active, not recruiting
Comparison of Needlescopic vs. Conventional Laparoscopic Adrenalectomy for Tumor Less Than 4 cm Starting soon
AI Based Physiotherapy 3- and 9-Month Follow-Up in Oral Cancer Patients Recruiting
Deep Versus Standard Prolonged Intermittent Theta Burst Stimulation for Depression Enrolling by invitation

Other trials for the same condition

A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients (TOPICS-THYROID) Active, not recruiting
Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment Active, not recruiting
Correlation Between Various Urinary Exosomal Protein Biomarkers and Pathological Manifestation in Thyroid Follicular Neoplasm: Early and Pre-operative Diagnosis of Follicular Thyroid Cancer Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04948437 on ClinicalTrials.gov ↗ ← All trials in Taiwan